Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). [electronic resource]
Producer: 20051102Description: 6854-64 p. digitalISSN:- 0732-183X
- Adjuvants, Immunologic -- adverse effects
- Adult
- Aged
- Aged, 80 and over
- Antibody Formation
- BCG Vaccine -- therapeutic use
- Carcinoma, Small Cell -- drug therapy
- Disease-Free Survival
- Drug Administration Schedule
- Ether-A-Go-Go Potassium Channels
- Female
- Humans
- Immunotherapy
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Nerve Tissue Proteins -- immunology
- Potassium Channels, Voltage-Gated -- immunology
- Quality of Life
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.